Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A combination study design to examine mycophenolate mofetil (MMF) and PTLDin renal transplant patients
Autore:
Kremers, HM; Funch, DP; Robson, RA; Nalesnik, MA; Ebrahim, S; Cecka, MJ; Opelz, G; Dreyer, NA; Walker, AM;
Indirizzi:
F Hoffmann La Roche & Co Ltd, Global Drug Safety, CH-4002 Basel, Switzerland F Hoffmann La Roche & Co Ltd Basel Switzerland CH-4002 asel, Switzerland Epidemiol Res Inst, Boston, MA USA Epidemiol Res Inst Boston MA USAEpidemiol Res Inst, Boston, MA USA Christchurch Hosp, Dept Nephrol, Christchurch, New Zealand Christchurch Hosp Christchurch New Zealand l, Christchurch, New Zealand Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA Univ Pittsburgh Pittsburgh PA USA burgh, Dept Pathol, Pittsburgh, PA USA Univ Pittsburgh, Div Transplantat, Pittsburgh, PA USA Univ Pittsburgh Pittsburgh PA USA , Div Transplantat, Pittsburgh, PA USA Univ Bristol, Dept Social Med, Bristol, Avon, England Univ Bristol Bristol Avon England ept Social Med, Bristol, Avon, England Univ Calif Los Angeles, UNOS Sci Renal Transplant Registry, Los Angeles, CA USA Univ Calif Los Angeles Los Angeles CA USA Registry, Los Angeles, CA USA Univ Heidelberg, Inst Immunol, Dept Transplantat Immunol, D-6900 Heidelberg, Germany Univ Heidelberg Heidelberg Germany D-6900 ol, D-6900 Heidelberg, Germany
Titolo Testata:
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
fascicolo: 7, volume: 8, anno: 1999,
pagine: 509 - 518
SICI:
1053-8569(199912)8:7<509:ACSDTE>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; EPSTEIN-BARR-VIRUS; ORGAN-TRANSPLANTATION; ALLOGRAFT RECIPIENTS; MALIGNANT DISEASE; CANCER; RISK; KIDNEY; DIALYSIS; OKT3;
Keywords:
transplantation; mycophenolate mofetil; posttransplant lymphoproliferative disorders; PTLD; pharmacoepidemiology; immunosuppression;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
64
Recensione:
Indirizzi per estratti:
Indirizzo: Kremers, HM F Hoffmann La Roche & Co Ltd, Global Drug Safety, Postfach 4070,Bld 74-1 OG-W, CH-4002 Basel, Switzerland F Hoffmann La Roche & Co Ltd Postfach 4070,Bld 74-1 OG-W Basel Switzerland CH-4002
Citazione:
H.M. Kremers et al., "A combination study design to examine mycophenolate mofetil (MMF) and PTLDin renal transplant patients", PHARMA D S, 8(7), 1999, pp. 509-518

Abstract

Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant. indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. Duringthe European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk ofPTLD in comparison with alternate immunosuppressive regimens. In response,F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 12:24:22